Bayer AG (BAYRY) Given Average Recommendation of “Buy” by Brokerages
Bayer AG (OTCMKTS:BAYRY) has been assigned a consensus rating of “Buy” from the twelve brokerages that are currently covering the company. Three analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $111.00.
Several equities research analysts have issued reports on the company. Zacks Investment Research raised Bayer AG from a “hold” rating to a “buy” rating and set a $111.00 price target for the company in a research note on Monday, October 17th. Sanford C. Bernstein reissued a “buy” rating on shares of Bayer AG in a research note on Thursday, September 15th. Goldman Sachs Group Inc. reissued a “buy” rating on shares of Bayer AG in a research note on Wednesday, September 14th. Finally, Citigroup Inc. raised Bayer AG from a “neutral” rating to a “buy” rating in a research note on Thursday, August 25th.
Shares of Bayer AG (OTCMKTS:BAYRY) traded down 0.85% during midday trading on Wednesday, hitting $93.67. The stock had a trading volume of 108,321 shares. The firm’s 50-day moving average price is $0.00 and its 200-day moving average price is $0.00. Bayer AG has a 1-year low of $92.84 and a 1-year high of $134.04.
Bayer AG (OTCMKTS:BAYRY) last posted its earnings results on Wednesday, October 26th. The company reported $1.93 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.13. Bayer AG had a return on equity of 24.12% and a net margin of 10.14%. On average, equities analysts expect that Bayer AG will post $8.07 earnings per share for the current year.
About Bayer AG
Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures.
Receive News & Stock Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related stocks with our FREE daily email newsletter.